NEBULA-1 AND NEBULA-2: PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS IN PROGRESS OF EFIMOSFERMIN ALFA IN PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND COMPENSATED CIRRHOSIS (AASLD 2026) - Oct 6, 2026 - Abstract #3558; Pres time: Nov 7, 2026; 01:00 PM - 02:00 PM; Location: Convention Center: Poster Hall, Hall DE; P2 | "NEBULA-1 and NEBULA-2 will evaluate the safety and efficacy of efimosfermin alfa in MASH with cirrhosis, using accepted regulatory primary endpoints with meaningful secondary and exploratory endpoints spanning noninvasive liver, metabolic, and measures of HRQoL. The data will inform whether efimosfermin alfa can modify disease progression and improve clinical outcomes in this high-risk population with a significant unmet need."
Clinical • P3 data • Fibrosis • Hepatocellular Cancer • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Solid Tumor • FGF21
|
|
Mazen Noureddin1; Naga Chalasani2; Meena Bansal3; Laurent Castera4; Rohit Loomba5; Arun Sanyal6; Margaret James Koziel7; Stuart Kendrick8; Beth Ann Reedy9; Theresa Peterson9; Andrea Ribeiro10; Patricia Mendez9; Jörn Schattenberg11
|